Journal Article

Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Scheper, Verena, Koch, Armin, Büchner, Andreas, Schwieger, Jana, von der Leyen, Heiko, Lenarz, Thomas, Schmidtheisler, Melanie, Lasch, Florian, Lesinski-Schiedat, Anke

2020

Overview

Background The standard therapy for patients suffering from sensorineural hearing loss is cochlear implantation. The insertion of the electrode array into the cochlea, with potential mechanical trauma and the presence of this foreign body inside the cochlea, may lead to free radical formation and reduced blood perfusion of the cochlea which can result in a loss of residual hearing. Studies have suggested that a particular combination of the antioxidants vitamins A, C and E as well as the vasodilator magnesium (together: ACEMg) may protect the residual hearing. Methods The potential protective effect of ACEMg on residual hearing preservation in cochlear implant (CI) patients was investigated in a single-centre, randomized, placebo-controlled, double-blind phase II clinical trial. CI candidates with some residual hearing in low frequencies receiving MED-EL implants of different FLEX electrode array lengths were treated with ACEMg tablets or placebo respectively 2 days preoperatively and up to 3 months postoperatively. The study objective was to demonstrate that ACEMg is more efficacious than placebo in preserving residual hearing during cochlear implantation by comparing the hearing loss (change in hearing thresholds at 500 Hz from baseline) 3 months after the first fitting between the two treatment groups and to investigate the treatments’ safety. Results Fifty-one patients were included in the study, which had to be terminated before the recruitment goal was reached because of IMP-resupply mismanagement of one partner. In the intention-to-treat population, 25 patients were treated with ACEMg and 24 patients with placebo. The mean hearing loss at 500 Hz was (± 15.84) 30.21 dB (placebo) or (± 17.56) 26.00 dB (ACEMg) 3 months after the initial fitting. Adjusting the postoperative hearing loss for the baseline residual hearing, planned electrode length and surgeon results in 8.01 dB reduced hearing loss in ACEMg-treated patients compared to placebo-treated ones. The safety analysis revealed that ACEMg was generally well-tolerated with adverse event frequencies below the placebo level. Conclusion This is the first clinical trial investigating a drug effect on residual hearing in CI patients. These first-in-man data may suggest that a perioperative oral administration of ACEMg is safe and may provide protection of residual hearing in CI patients. Trial registration EU Clinical Trial Register No. 2012-005002-22 . Registered on 6 December 2013. Funding: European Commission FP7-HEALTH-2012-INNOVATION-2.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Acoustics / Adult / Aged / Antioxidants / Antioxidants (Nutrients) / Antioxidants - therapeutic use / Biomedicine / Care and treatment / Clinical trials / Cochlear implant / Cochlear Implantation / Cochlear Implants / Double-Blind Method / Ear prostheses / Electrodes / Female / Free radical scavengers / Free radicals / Health aspects / Health Sciences / Hearing disorders / Hearing loss / Hearing Loss - prevention & control / Hearing pill / Hearing preservation / Humans / Magnesium - therapeutic use / Male / Medicine / Medicine & Public Health / Middle Aged / Oxidative stress / Patient outcomes / Patients / Statistics for Life Sciences / Surgery / Treatment Outcome / Vasodilator agents / Vasodilator Agents - therapeutic use / Vitamin C / Vitamin E / Vitamins - therapeutic use